Use of calcium antagonists in patients with ischemic heart disease and systemic hypertension

The American Journal of Cardiology
W H Frishman, M D Michaelson

Abstract

Ischemic heart disease (IHD) and systemic hypertension commonly coexist in a large number of patients, and the presence of hypertension is a risk factor for worsening IHD. A monotherapy that would effectively treat both is thus an attractive idea, and calcium antagonists have been evaluated in this role. Calcium antagonists exert therapeutic effects through a combination of actions, including systemic and peripheral vasodilation, negative inotropy, and reduced nodal conduction. In randomized, double-blind clinical trials, verapamil compares favorably with propranolol in the alleviation of angina and hypertension. Both diltiazem and nifedipine, as well as long-acting diltiazem, are also effective in treating the combined condition. In addition, each of these drugs enhances exercise tolerance and favors compliance with calcium antagonist therapy. Recent questions regarding the safety of this class of drug have tempered the enthusiasm for their use as first-line therapy in cardiovascular disease. In particular, short-acting dihydropyridine derivatives, including nifedipine and isradipine, may increase cardiovascular morbidity and mortality because of reflex sympathetic stimulation. The results of appropriately controlled, prospect...Continue Reading

References

Nov 23, 1976·The American Journal of Cardiology·W Hollander
Jan 1, 1991·Journal of Cardiovascular Pharmacology·W H Frishman
Jan 1, 1988·Journal of Cardiovascular Pharmacology·W H Frishman, E J Lazar
Feb 26, 1986·The American Journal of Cardiology·W H FrishmanN Klein
Dec 6, 1985·The American Journal of Cardiology·W H FrishmanJ Strom
Jan 1, 1982·European Journal of Clinical Pharmacology·S E HustedO Lederballe Pedersen
Nov 13, 1995·Archives of Internal Medicine·T C Fagan
Nov 13, 1995·Archives of Internal Medicine·C D Furberg, B M Psaty
Jul 1, 1996·Journal of the American College of Cardiology·S BraunU Goldbourt

❮ Previous
Next ❯

Citations

Aug 7, 2001·British Journal of Pharmacology·S Berjukow, S Hering
Mar 4, 2008·Biological & Pharmaceutical Bulletin·Daiki TakahashiShizuo Yamada
Feb 2, 2016·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Kacper DrużbickiJan Wąsicki
Jan 7, 2004·The American Journal of Medicine·Mark J EisenbergAlain N Bestawros

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Cardiac Conduction System

The cardiac conduction system is a specialized tract of myocardial cells responsible for maintaining normal cardiac rhythm. Discover the latest research on the cardiac conduction system here.

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

Cardiovascular Diseases: Risk Factors

Cardiovascular disease is a significant health concern. Risk factors include hypertension, obesity, dyslipidemia and smoking. Women who are postmenopausal are at an increased risk of heart disease. Here is the latest research for risk factors of cardiovascular disease.

Antianginal Drugs: Mechanisms of Action

Antianginal drugs, including nitrates, beta-blockers, and calcium channel blockers, are used in the treatment of angina pectoris. Here is the latest research on their use and their mechanism of action.